Alfredo Lozada/LinkedIn
Sep 11, 2026, 09:51
Alfredo Lozada: Pelacarsen Lowers Lp(a), But Does It Lower CV Risk?
Alfredo Lozada, Founder of Clinica del Colesterol at Cholesterol Clinic, shared a post on LinkedIn:
“Futility of Pelacarsen in the Lipoprotein(a) HORIZON !!
8,323 people with Lpa and CV disease. Designed to prove a reduction CV events .
Pelacarsen lowered Lp(a), but the study did not reduce CV Events.
- Important information, has not been presented. For patients, the message is clear: this announcement does not change the genetics & management of Lp(a). For clinicians, keep driving LDL-C to target, blood pressure, and managing risk factors.
- Maybe patients need to start reducing Lpa much earlier to get benefit. The Diminishing Returns graph & theory attached, shows that earlier Tx is needed !! As with inflammation you need to fight the fire, not the ashes !!
We wait the data release from other ongoing outcome trials to understand the next steps in CV prevention. What will you do at home?”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning